No Survival Benefit With Ipilimumab in Advanced Prostate Cancer

In a phase III trial, ipilimumab increased the overall survival of men with advanced castration-resistant prostate cancer when used with a single dose of radiotherapy by 1.2 months, but the results were not statistically significant.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news